Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada.
We were honored to be mentioned by Acadia Pharmaceuticals.
Priority Review by Health Canada
Last Updated: 06/22/2024 by Steve
Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada.
We were honored to be mentioned by Acadia Pharmaceuticals.
See the video below.
Category: News, Top Slider, What's New Tags: 2024, Acadia, Health Canada